blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1109576

EP1109576 - IMMUNOGENIC BETA-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.08.2010
Database last updated on 11.09.2024
Most recent event   Tooltip28.09.2012Lapse of the patent in a contracting state
New state(s): NL		published on 31.10.2012  [2012/44]
Applicant(s)For all designated states
Baxter Healthcare SA
Hertistrasse 2
8306 Wallisellen / CH
[2003/50]
Former [2003/46]For all designated states
Baxter Healthcare SA
Hertistrasse 2
8304 Wallisellen / CH
Former [2001/26]For all designated states
NORTH AMERICAN VACCINE, INC.
10150 Old Columbia Road
Columbia, MD 21046 / CA
Inventor(s)01 / MICHON, Francis
4401 Rosedale Avenue
Bethesda, MD 20814 / US
02 / HUANG, Chun-Hsien
9815 Bald Cypress Drive
Bethesda, MD 20850 / US
03 / UITZ, Catherine
4126 North 34th Road
Arlington, VA 22207 / US
 [2001/26]
Representative(s)Miles, John Stephen, et al
Potter Clarkson LLP The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
[N/P]
Former [2003/46]Miles, John Stephen, et al
Eric Potter Clarkson, Park View House, 58 The Ropewalk
Nottingham NG1 5DD / GB
Former [2001/26]Miles, John Stephen
Eric Potter Clarkson, Park View House, 58 The Ropewalk
Nottingham NG1 5DD / GB
Application number, filing date99945115.618.08.1999
[2001/26]
WO1999US18982
Priority number, dateUS19980097120P19.08.1998         Original published format: US 97120 P
US1999037691118.08.1999         Original published format: US 376911
[2001/26]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO0010599
Date:02.03.2000
Language:EN
[2000/09]
Type: A2 Application without search report 
No.:EP1109576
Date:27.06.2001
Language:EN
The application published by WIPO in one of the EPO official languages on 02.03.2000 takes the place of the publication of the European patent application.
[2001/26]
Type: B1 Patent specification 
No.:EP1109576
Date:21.10.2009
Language:EN
[2009/43]
Search report(s)International search report - published on:EP22.06.2000
ClassificationIPC:A61K39/385
[2001/26]
CPC:
A61K39/385 (EP,KR,US); A61K47/646 (EP,US); A61P31/04 (EP);
A61P35/00 (EP); A61P37/04 (EP); A61K2039/54 (EP);
A61K2039/6031 (EP,US); A61K2039/6037 (EP,US); A61K2039/627 (EP,US);
Y02A50/30 (EP) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2001/26]
Extension statesSI19.03.2001
TitleGerman:IMMUNOGENES BETA-PROPIONAMIDO-GEBUNDENES POLYSACCHARID-PROTEIN KONJUGAT GEEIGNET ALS IMPFSTOFF UND HERGESTELLT BEI VERWENDUNG VON N-ACRYLOYLIERTEM POLYSACCHARID[2001/26]
English:IMMUNOGENIC BETA-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE[2001/26]
French:CONJUGUE DE PROTEINE-POLYSACCHARIDE IMMUNOGENE A LIAISON BETA-PROPIONAMIDO, UTILE COMME VACCIN ETABLI AU MOYEN D'UN POLYSACCHARIDE N-ACRYLOYLE[2001/26]
Entry into regional phase19.03.2001National basic fee paid 
19.03.2001Designation fee(s) paid 
19.03.2001Examination fee paid 
Examination procedure21.02.2000Request for preliminary examination filed
International Preliminary Examining Authority: EP
19.03.2001Examination requested  [2001/26]
20.03.2001Amendment by applicant (claims and/or description)
22.07.2005Despatch of a communication from the examining division (Time limit: M06)
01.02.2006Reply to a communication from the examining division
17.03.2009Communication of intention to grant the patent
27.07.2009Fee for grant paid
27.07.2009Fee for publishing/printing paid
Opposition(s)22.07.2010No opposition filed within time limit [2010/39]
Fees paidRenewal fee
21.08.2001Renewal fee patent year 03
21.08.2002Renewal fee patent year 04
25.08.2003Renewal fee patent year 05
23.08.2004Renewal fee patent year 06
19.08.2005Renewal fee patent year 07
29.08.2006Renewal fee patent year 08
29.08.2007Renewal fee patent year 09
25.08.2008Renewal fee patent year 10
25.08.2009Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT21.10.2009
BE21.10.2009
CY21.10.2009
DK21.10.2009
FI21.10.2009
IT21.10.2009
NL21.10.2009
SE21.10.2009
GR22.01.2010
ES01.02.2010
PT22.02.2010
[2012/44]
Former [2012/37]AT21.10.2009
BE21.10.2009
CY21.10.2009
DK21.10.2009
FI21.10.2009
IT21.10.2009
SE21.10.2009
GR22.01.2010
ES01.02.2010
PT22.02.2010
Former [2011/25]AT21.10.2009
BE21.10.2009
DK21.10.2009
FI21.10.2009
IT21.10.2009
SE21.10.2009
GR22.01.2010
ES01.02.2010
PT22.02.2010
Former [2010/44]AT21.10.2009
BE21.10.2009
DK21.10.2009
FI21.10.2009
SE21.10.2009
ES01.02.2010
PT22.02.2010
Former [2010/29]AT21.10.2009
BE21.10.2009
FI21.10.2009
SE21.10.2009
ES01.02.2010
PT22.02.2010
Former [2010/28]FI21.10.2009
SE21.10.2009
ES01.02.2010
PT22.02.2010
Former [2010/19]ES01.02.2010
Cited inInternational search[A]US4356170  (JENNINGS HAROLD J, et al) [A] 1-58* examples 1-3; claims 1-26 *;
 [XY]US4727136  (JENNINGS HAROLD J [CA], et al) [X] 15,48-58 * column 1, line 1 - column 8, line 39 * [Y] 1-14,16-47;
 [XY]US5576002  (JENNINGS HAROLD J [CA], et al) [X] 15,48-58 * column 3, line 7 - column 11, line 5; claims 1-38 * [Y] 1-14,16-47;
 [X]WO9640239  (CA NAT RESEARCH COUNCIL [CA]) [X] 1-58 * page 1, line 24 - page 9, line 35; examples 1-8; tables 1-3 *;
 [XY]  - JENNINGS H J ET AL, "Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine.", JOURNAL OF IMMUNOLOGY, (1986 SEP 1) 137 (5) 1708-13., XP002052677 [X] 15,48-58 * abstract, "materials and methods" starting at page 1708 and "discussion" starting at page 1711 * [Y] 1-14,16-47
 [XY]  - JENNINGS H J ET AL, "Unique intermolecular bactericidal epitope involving the homosialopolysaccharide capsule on the cell surface of group B Neisseria meningitidis and Escherichia coli K1.", JOURNAL OF IMMUNOLOGY, (1989 MAY 15) 142 (10) 3585-91., XP000872571 [X] 15,48-58 * abstract * [Y] 1-14,16-47
 [XY]  - FUSCO P C ET AL, "Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates.", JOURNAL OF INFECTIOUS DISEASES, (1997 FEB) 175 (2) 364-72., XP000291371 [X] 15,48-58 * abstract * * page 364, column 2, paragraph 3 - page 366, column 2, paragraph 2 * [Y] 1-14,16-47
 [XY]  - FUSCO, PETER C. ET AL, "Meningococcal vaccine development: a novel approach", EXPERT OPIN. INVEST. DRUGS (1998), 7(2), 245-252, XP000872557 [X] 15,48-58 * abstract * * page 245, line 1 - page 247, column 1, paragraph 1 * [Y] 1-14,16-47

DOI:   http://dx.doi.org/10.1517/13543784.7.2.245
 [XY]  - GRANOFF D M ET AL, "Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid.", JOURNAL OF IMMUNOLOGY, (1998 MAY 15) 160 (10) 5028-36., XP000872887 [X] 15,48-58 * abstract and "materials and methods" starting at page 5029 * [Y] 1-14,16-47
 [XY]  - JENNINGS H J ET AL, "Chemically modified Group B meninggococcal polysaccharides as human vaccines", PROCEEDINGS OF THE NATIONAL MEETING: SYMPOSIUM ON THE APPLICATIONS AND MODIFICATIONS OF INDUSTRIAL POLYSACCHARIDES,NL,AMSTERDAM, ELSEVIER, (1987), vol. MEETING 193, pages 149 - 156, XP002016901 [X] 15,48-58 * page 150, line 9 - page 156, line 3 * [Y] 1-14,16-47
Examination   - W.E. DICK ET AL., "Glycoconjugates of Bacterial carbohydrate Antigens.", CONJUGATE VACCINES, (1989), vol. 10, pages 48 - 114
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.